| |
Univariate analysis
|
Multivariate analysis
|
|---|
|
HR (95% CI)
|
P-value
|
HR (95% CI)
|
P-value
|
|---|
|
Age#
|
≤30
|
NA§
| |
NA§
| |
| |
31-40
|
1 (reference)
| |
1 (reference)
| |
| |
41-50
|
0.88 (0.43–1.81)
|
0.721
|
0.64 (0.25–1.62)
|
0.343
|
| |
51-60
|
0.67 (0.31–1.47)
|
0.318
|
0.83 (0.32–2.15)
|
0.705
|
| |
61-70
|
1.17 (0.52–2.66)
|
0.704
|
0.96 (0.30–3.08)
|
0.949
|
| |
≥71
|
0.51 (0.11–2.29)
|
0.376
|
0.52 (0.06–4.73)
|
0.564
|
|
Alcohol#
|
No
|
1 (reference)
| |
1 (reference)
| |
| |
Yes
|
1.03 (0.62–1.74)
|
0.899
|
1.07 (0.54–2.11)
|
0.842
|
|
Smoking#
|
No
|
1 (reference)
| |
1 (reference)
| |
| |
Yes
|
1.44 (0.71–2.93)
|
0.315
|
1.98 (0.79–4.97)
|
0.145
|
|
Betel nut#
|
No
|
1 (reference)
| |
1 (reference)
| |
| |
Yes
|
1.64 (0.83–3.26)
|
0.156
|
1.00 (0.42–2.37)
|
0.999
|
|
TNM staging#
|
1
|
1 (reference)
| |
1 (reference)
| |
| |
2
|
1.18 (0.50–2.78)
|
0.703
|
0.76 (0.26–2.23)
|
0.618
|
| |
3
|
2.35 (0.95–5.86)
|
0.066
|
2.16 (0.78–6.02)
|
0.140
|
| |
4
|
4.21 (2.12–8.40)
|
<0.001
|
3.53 (1.41–8.81)
|
0.007
|
|
EGFR
|
Negative
|
1 (reference)
| | | |
| |
Positive
|
1.19 (0.70–2.02)
|
0.516
|
NA
| |
|
EGFR GCN
|
Non-amplified
|
1 (reference)
| | | |
| |
Amplified
|
0.94 (0.57–1.57)
|
0.822
|
NA
| |
|
EGFRvIII#
|
Low
|
1 (reference)
| | | |
| |
High
|
2.27 (1.36–3.79)
|
0.002
|
1.98 (1.01–3.87)
|
0.046
|
|
PTEN
|
Negative
|
1 (reference)
| | | |
| |
Positive
|
1.26 (0.77–2.08)
|
0.359
|
NA
| |
|
pAKT#
|
Negative
|
1 (reference)
| | | |
| |
Positive
|
2.51 (1.00–6.27)
|
0.050
|
2.67 (1.01–7.07)
|
0.049
|
- CI confidence interval, HR hazard ratio, NA not assessed.
- #Factors included in multivariate analysis.
- §Not assessed because the patient number was too small.
